Journal list Promote Sponsor
verified SJR 0,725 · Q2 • database Scopus / SJR & Web of Science indexed
Journal of Clinical Psychopharmacology
United States · Lippincott Williams and Wilk...
workspace_premium Q2 — Psychiatry and Mental Health lock Subscription

Journal of Clinical Psychopharmacology

Journal of Clinical Psychopharmacology is a journal indexed in SJR in Psychiatry and Mental Health and Pharmacology (medical) with an H index of 135. It has a price of 2083 €. It has an SJR impact factor of 0,725 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,725.

Journal of Clinical Psychopharmacology focuses its scope in these topics and keywords: efficacy, alcohol, treatment, study, patients, lithium, anxiety, syndrome, trazodone, treated, ...

ISSN: 0271-0749
Publisher: Lippincott Williams and Wilkins Ltd.
Category: Psychiatry and Mental Health
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
0,725 Q2
H-index 135
Acceptance rate pie_chart
23% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
2.083 € Subscription
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,725

H-index

135

Docs (year)

161

Docs 3y

441

Total refs

4180

Cites 3y

625

Citable 3y

221

Cites/Doc 2y

1.27

Ref/Doc

25.96

Immediate OA

2083 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Asenapine-Associated Myasthenic Syndrome

View more

Weight Loss Associated With Olanzapine Treatment

View more

Clozapine-Induced Myoclonus

View more

Cerebral Monoamine Oxidase A Inhibition in Tobacco Smokers Confirmed With PET and [11C]Befloxatone

View more

Catatonia in Outpatients

View more

Burning Paresthesia Related to Duloxetine Therapy

View more

Bulimia Nervosa, 5-HTTLPR Polymorphism and Treatment Response to Four SSRIs

View more

Brain Cytokines and Neuropsychiatric Disorders

View more

Baclofen Suppresses Alcohol Intake and Craving for Alcohol in a Schizophrenic Alcohol-Dependent Patient

View more

Baclofen as Relapse Prevention in the Treatment of Gamma-Hydroxybutyrate Dependence

View more

Baclofen as Adjunctive Treatment for a Patient With Cocaine Dependence and Schizoaffective Disorder

View more

Author Index

View more
SHOW MORE ARTICLES

Author Index

View more

"Comments on Article by Tran and Colleagues, ""Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders"

View more

Aripiprazole May Be Effective as an Add-on Treatment in Bulimic Symptoms of Eating Disorders

View more

Are Gender Differences in Antiobsessional Response Related to Different Clomipramine Metabolism?

View more

Anandamide Is Involved in Appetite-Related Amygdala Hyperactivations in Schizophrenia Patients Treated With Olanzapine

View more

Amisulpride for Older Patients With Long-Standing Schizophrenia

View more

Activity of Citalopram on Adenosine and Serotonin Circulating Levels in Depressed Patients

View more

A Tribute to Dr. Hermann R. Ochs, 1943-2013

View more

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression

View more

A Double-Blind, Randomized, Prospective Evaluation of the Efficacy and Safety of Risperidone Versus Haloperidol in the Treatment of Schizoaffective Disorder

View more

A Case of Drug Dependence Syndrome to Baclofen Following High-Dose Therapy

View more

A 2-Year, Open-Label Pilot Study of Adjunctive Chromium in Patients With Treatment-Resistant Rapid-Cycling Bipolar Disorder

View more

FAQs